Physician profile
Adam R Easterling
NPI 1679603922
$8,187.43
in general payments reported to CMS, 2019-2025
27 companies · $1,341 in 2025
The $1,341 reported for 2025 was more than what 83% of Ophthalmology providers received nationally (typical 2025 total: $384).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,694 · 2020: $673 · 2021: $891 · 2022: $1,546 · 2023: $964 · 2024: $1,079 · 2025: $1,341.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,384.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,384.20 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alcon Vision LLC | $4,723.95 | 2019-2025 | Clareon, Centurion, Clareon Panoptix Pro |
| Sight Sciences, INC. | $319.40 | 2022-2025 | Omni Surgical System, Sion Surgical Instrument |
| Johnson & Johnson Surgical Vision, INC. | $304.37 | 2019-2021 | |
| Bausch & Lomb Americas INC. | $288.45 | 2022-2025 | Vyzulta, Miebo, Xiidra |
| Ocular Therapeutix, INC. | $252.85 | 2020-2025 | Dextenza |
| Oyster Point Pharma, INC. | $240.86 | 2022-2025 | Tyrvaya |
| Sun Pharmaceutical Industries INC. | $240.03 | 2019-2024 | |
| Glaukos Corporation | $205.27 | 2019-2025 | Idosetr, Istent Infinite |
| Allergan, INC. | $180.17 | 2019-2022 | |
| Rayner Intraocular Lenses Limited | $177.85 | 2023-2024 | Rayone Spheric, Rayone Aspheric, Rayone Emv |
| Ivantis, INC | $177.48 | 2020-2021 | |
| Tearlab Corp | $174.24 | 2019 | |
| Abbvie INC. | $154.26 | 2022-2025 | |
| Omeros Corporation | $125.24 | 2019-2021 | |
| Carl Zeiss Meditec, INC. | $120.31 | 2019 |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Bausch & Lomb, A Division of Bausch Health US, LLC | $108.06 | 2019-2021 | |
| Novartis Pharmaceuticals Corporation | $78.02 | 2019-2022 | |
| Harrow Eye, LLC | $63.95 | 2024-2025 | Vevye |
| Tarsus Pharmaceuticals, INC. | $60.09 | 2025 | Xdemvy |
| Biotissue Holdings INC. | $35.95 | 2021-2022 | |
| Kala Pharmaceuticals, INC. | $33.78 | 2019-2021 | |
| Coherus Oncology, INC. | $27.91 | 2022 | |
| Dompe US, INC. | $27.70 | 2025 | Oxervate |
| Apellis Pharmaceuticals, INC. | $22.08 | 2022 | |
| Genentech USA, INC. | $15.94 | 2024 | Susvimo |
| Alimera Sciences, INC. | $15.73 | 2023 | Iluvien |
| Shire North American Group INC | $13.49 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Adam Easterling listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.